Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD surveillance network, 2009-2010

Emerging Infectious Diseases

Volumn 18, Issue 6, 2012, Pages 939-943

  Kirkcaldy, Robert D ^a   Augostini, Peter ^a   Asbel, Lenore E ^b   Bernstein, Kyle T ^c   Kerani, Roxanne P ^d   Mettenbrink, Christie J ^e   Pathela, Preeti ^f   Schwebke, Jane R ^g,h   Evan Secor, W ^a   Workowski, Kimberly A ^a,i   Davis, Darlene ^a   Braxton, Jim ^a   Weinstock, Hillard S ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b PHILADELPHIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^c SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^d Public Health Seattle Seattle WA and King County   (United States)

^e DENVER PUBLIC HEALTH   (United States)

^f NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^g Jefferson County Department of Health   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; TINIDAZOLE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MINIMUM LETHAL CONCENTRATION; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SENTINEL SURVEILLANCE; SEXUALLY TRANSMITTED DISEASES; SEXUALLY TRANSMITTED DISEASES, BACTERIAL; TRICHOMONAS VAGINALIS; TRICHOMONAS VAGINITIS; UNITED STATES; YOUNG ADULT;

EID: 84861214559     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1806.111590     Document Type: Article

References (19)

1. World Health Organization. Prevalence and incidence of selected sexually transmitted infections, Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis: methods and results used by WHO to generate 2005 estimates. Geneva: the Organization; 2011 [cited 2012 Jan 31]. http://whqlibdoc.who.int/publications/2011/9789241502450_eng.pdf
2. Weinstock H, Berman S, Cates W. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36:6-10. http://dx.doi.org/10.1363/3600604
3. Sutton M, Sternberg M, Koumans EH, McQuillan G, Berman S. Markowitz. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004. Clin Infect Dis. 2007;45:1319-26. http://dx.doi.org/10.1086/522532
4. Cotch MF, Pastorek JG, Nugent RP, Hillier SL, Gibbs RS, Martin DH, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm Dis. 1997;24:353-60. http://dx.doi.org/10.1097/00007435-199707000-00008
5. Minkoff H, Grunebaum AN, Schwarz R, Feldman J, Cummings M, Crombleholme W, et al. Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. Am J Obstet Gynecol. 1984;150:965-72.
6. Moodley P, Wilkinson D, Connolly C, Moodley J, Sturm AW. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis. 2002;34:519-22. http://dx.doi.org/10.1086/338399
7. McClelland RS, Sangare L, Hassan WM, Feldman J, Cummings M, Crombleholme W, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis. 2007;195:698-702. http://dx.doi.org/10.1086/511278
8. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59:1-110.
9. Schmid G, Narcisi E, Mosure D, Secor WE, Higgins J, Moreno H. Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med. 2001;46:545-9.
10. Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother. 2006;50:4209-10. http://dx.doi.org/10.1128/AAC.00814-06
11. Krashin JW, Koumans EH, Bradshaw-Sydnor AC, Braxton JR, Evan Secor W, Sawyer MK, et al. Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population. Sex Transm Dis. 2010;37:440-4.
12. Meingassner JG, Thurne J. Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles. Antimicrob Agents Chemother. 1979;15:254-7.
13. Lossick JG, Müller M, Gorrell TE. In vitro drug susceptibility and doses of metronidazole required for cure in cases of refractory vaginal trichomoniasis. J Infect Dis. 1986;153:948-55. http://dx.doi.org/10.1093/infdis/153.5.948
14. Pérez S, Fernández-Verdugo A, Pérez F, Vázquez F. Prevalence of 5-nitroimidazole-resistant Trichomonas vaginalis in Oviedo, Spain. Sex Transm Dis. 2001;28:115-6. http://dx.doi.org/10.1097/00007435-200102000-00010
15. Upcroft JA, Dunn LA, Wal T, Tabrizi S, Delgadillo-Correa MG, Johnson PJ, et al. Metronidazole resistance in Trichomonas vaginalis from highland women in Papua New Guinea. Sex Health. 2009;6:334-8. http://dx.doi.org/10.1071/SH09011
16. Das S, Huengsberg M, Shahmanesh M. Treatment failure of vaginal trichomoniasis in clinical practice. Int J STD AIDS. 2005;16:284-6. http://dx.doi.org/10.1258/0956462053654258
17. Bosserman EA, Helms DJ, Mosure DJ, Secor WE, Workowski KA. Utility of antimicrobial susceptibility testing in Trichomonas vaginalis- infected women with clinical treatment failure. Sex Transm Dis. 2011;38:983-7. http://dx.doi.org/10.1097/OLQ.0b013e318224db39
18. Crowell AL, Sanders-Lewis AK, Secor WE. In vitro comparison of metronidazole and tinidazole activity against metronidazole-resistant strains of Trichomonas vaginalis. Antimicrob Agents Chemother. 2003;47:1407-9. http://dx.doi.org/10.1128/AAC.47.4.1407-1409.2003
19. Wood BA, Monro AM. Pharmacokinetics of tinidazole and metronidazole in women after single large doses. Br J Vener Dis. 1975;51:51-3.